[1]安 琦,芦希艳,王 伟,等.抗激护肠方治疗腹泻型肠易激综合征临床研究[J].陕西中医,2023,(10):1382-1386.[doi:DOI:10.3969/j.issn.1000-7369.2023.10.010]
　AN Qi,LU Xiyan,WANG Wei,et al.Diarrhea irritable bowel syndrome patients treated by Kangji Huchang formula[J].,2023,(10):1382-1386.[doi:DOI:10.3969/j.issn.1000-7369.2023.10.010]
点击复制

抗激护肠方治疗腹泻型肠易激综合征临床研究
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2023年10期
页码:
1382-1386
栏目:
临床研究
出版日期:
2023-10-05

文章信息/Info

Title:
Diarrhea irritable bowel syndrome patients treated by Kangji Huchang formula
作者:
安 琦1; 芦希艳1; 王 伟1; 安 荣2; 冯军强3
(1.空军军医大学唐都医院,陕西 西安 710038; 2.陕西中医药大学,陕西 咸阳 712046; 3.西安国际医学中心医院,陕西 西安 710100)
Author(s):
AN Qi; LU Xiyan; WANG Wei; AN Rong; FENG Junqiang
(Tangdu Hospital of Air Force Medical University,Xi'an 710038,China)
关键词:
肠易激综合征;  腹泻型;  抗激护肠方;  匹维溴铵;  肠黏膜屏障;  炎性因子;  脑肠肽
Keywords:
Irritable bowel syndrome;  Diarrhea type;  Kangji Huchang formula;  Pinaverium bromide;  Intestinal mucosal barrier;  Inflammatory factors;  Brain-gut peptide
分类号:
R 574
DOI:
DOI:10.3969/j.issn.1000-7369.2023.10.010
文献标志码:
A
摘要:
目的:分析抗激护肠方治疗腹泻型肠易激综合征(IBS-D)患者的临床治疗效果。方法:选取80例IBS-D患者,随机分为两组。对照组口服匹维溴铵片,观察组口服抗激护肠方。观察两组临床疗效,比较两组患者治疗前后中医症候积分、中华生存质量量表(ChQOL)评分以及相关实验室指标:二胺氧化酶(DAO)、D-乳酸(D-LA)、肠脂肪酸结合蛋白(I-FABP)、肿瘤坏死因子-α(TNF-α)、降钙素相关基因肽(CGRP)、白介素-10(IL-10)、神经肽Y(NPY)。结果:观察组临床有效率明显高于对照组(P<0.05)。治疗后,对照组患者的大便频次、性状、腹痛积分与本组治疗前比较均下降(P<0.05),但总积分比较差异无统计学意义(P>0.05); 观察组各项积分及总积分较治疗前均显著降低,差异有统计学意义(P<0.05),且观察组积分与对照组比较明显下降,差异有统计学意义(P<0.05)。治疗后,两组患者相关实验室指标分别优于各组治疗前,且观察组各指标明显优于对照组(P<0.05)。对照组治疗后ChQOL评分与治疗前比较,差异无统计学意义(P>0.05); 观察组治疗后ChQOL评分较治疗前提高,差异有统计学意义(P<0.05),且治疗后观察组评分与对照组比较明显升高,差异有统计学意义(P<0.05)。观察组与对照组不良反应发生例数比较差异有统计学意义(P<0.05)。结论:抗激护肠方能明显减轻IBS-D患者临床症状,其机制可能与修复肠黏膜、减轻炎性反应、调控脑-肠轴功能有关。
Abstract:
Objective:To analyze the clinical therapeutic effect of Kangji Huchang formula on patients with diarrhea type irritable bowel syndrome.Methods:Eighty patients with diarrhea irritable bowel syndrome were randomly divided into two groups.The control group was treated the pinaverium bromide tablets orally,while the observation group was orally treated with the Kangji Huchang formula.After treatment,observe the curative effect,and compare the TCM syndrome score,Chinese Quality of Life Scale(ChQOL)score,diamine oxidase(DAO),D-lactic acid(D-LA),intestinal fatty acid binding protein(I-FABP),and tumor necrosis factor(TNF)of the two groups of patients before and after treatment-α(TNF-α)、content of calcitonin related gene peptide(CGRP),interleukin 10(IL-10),and neuropeptide Y(NPY).Results:The effective rate of observation group was higher than that of control group(P<0.05).After treatment,the stool frequency,characteristics,and abdominal pain scores of patients in the control group decreased compared with those before treatment in this group(P<0.05).However,there was no statistically significant difference in total score between the control group before and after treatment(P>0.05).In the observation group,the sub scores and total score of traditional Chinese medicine symptoms were significantly reduced compared to before treatment(P<0.05).The traditional Chinese medicine symptoms scores in the observation group decreased significantly compared to the control group,with a statistical difference(P<0.05).After treatment,the relevant laboratory indexes of the two groups were better than those before treatment,and the indexes of observation group were significantly better than those of control group(P<0.05).There was no statistically significant difference in the quality score of the Chinese Quality of Life Scale(ChQOL)between the control group after treatment and before treatment(P>0.05).The ChQOL score of the observation group after treatment improved compared to before treatment(P<0.05).And there was a significant increase in the score of the observation group compared to the control group after treatment(P<0.05).During the treatment period,the number of adverse reactions in the observation group and control group was statistical differences between the two groups(P<0.05).Conclusion:Kangji Huchang formula can significantly alleviate various discomfort symptoms in patients,with significant clinical efficacy.It's mechanism may be related to repairing intestinal mucosa,reducing inflammatory reactions,and regulating the function of the brain intestinal axis.

参考文献/References:

[1] 周 滔,谭海成,杨仲婷,等.健脾温肾巴布剂穴位贴敷法治疗脾肾阳虚型腹泻型肠易激综合征临床观察[J].中华中医药杂志,2020,35(11):5858-5862.
[2] 李海燕,施 思,孙 红,等.灵龟八法择时取穴雷火灸治疗脾肾阳虚腹泻型肠易激综合征的临床效果[J].中国医药导报,2021,18(23):135-139.
[3] Brenner DM,Sayuk GS,Gutman CR,et al.Efficacy and safety of eluxadoline in patients with irritable bowel syndrome with diarrhea who report inadequate symptom control with loperamide:RELIEF phase 4 study[J].Am J Gastroenterol,2019,114(9):132-138.
[4] Ford AC,Moayyedi P,Chey WD,et al.American college of gastroenterology monograph on management of irritable bowel syndrome[J].Am J Gastroenterol,2018,113(2):157-164.
[5] Song KH,Jung HK,Kim HJ,et al.Clinical practice guidelines for irritable bowel syndrome in korea,2017 revised edition[J].Journal of Neurogastroenterology and Motility,2018,24(2):197-215.
[6] Wu JC,Chan AO,Chan YW,et al.The current treatment landscape of irritable bowel syndrome in adults in Hong Kong:Consensus statements[J].Hong Kong Med J,2017,23(6):641-654.
[7] 中华医学会消化病学会胃肠功能性疾病协作组,中华医学会消化病学分会胃肠动力学组.2020年中国肠易激综合征专家共识意见[J].中华消化杂志,2020,40(12):803-818.
[8] 国家食品药品监督管理总局.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002:139-143.
[9] 潘以丰,蔡海荣,李志雄,等.中华生活质量量表应用于肠易激综合征的信度与效度评价[J].山东中医杂志,2019,38(3):233-237.
[10] 许月月,陈 敏,谢 欣,等.从“脾为之卫”浅析腹泻型肠易激综合征肠黏膜机械屏障损伤机制[J].陕西中医,2021,42(8):1096-1099.
[11] 罗文昭,李晓宁,周雨慧,等.中药治疗肠易激综合征的用药规律[J].中医学报,2022,37(29):1517-1576.
[12] 徐宏喜.中药药理学[M].3版.上海:上海科学技术出版社,2019:69-227.
[13] Lacy BE.Diagnosis and treatment of diarrhea-predominant irritable bowel syndrome[J].International Journal of General Medicine,2016,9:7-17.
[14] 黄 礼,韦 祎,刘英莲.加味异功散辅助马来酸曲美布汀治疗腹泻型肠易激综合征疗效及对结肠组织酪酪肽和密封蛋白1表达的影响[J].广州中医药大学学报,2022,39(3):508-515.
[15] Annaházi A,Ferrier L,Bezirard V,et al.Luminal cysteine-proteases degrade colonic tight junction structure and are responsible for abdominal pain in constipation-predominant IBS[J].Am J Gastroenterol,2013,108(8):1322-1331.
[16] 蔡林坤,黄 适,彭卓嵛,等.安肠汤治疗腹泻型肠易激综合征肝郁脾虚证的临床疗效及其对肠屏障功能、炎性因子、神经肽Y水平的影响研究[J].中国全科医学,2020,23(9):1169-1174.
[17] 魏 薇,王慧芬,于 康,等.腹泻型肠易激综合征患者膳食纤维摄入与肠屏障功能的相关性探究[J].中华临床营养杂志,2022,30(4):206-213.
[18] 张 续,赵莉平,安 荣.肠易激综合征生物标志物研究进展[J].陕西医学杂志,2022,51(8):1038-1041.
[19] 田永超.脓毒症肠黏膜屏障功能障碍防治研究进展[J].陕西医学杂志,2020,49(4):510-513.
[20] 徐 蔚,费松柏,田爱霞,等.热敏灸联合匹维溴铵治疗腹泻型肠易激综合征的疗效观察及对血清NGF、TNF-α的影响[J].上海针灸杂志,2020,39(9):1094-1098.
[21] 林雪冬,王玲玲,黄小燕,等.隔药灸神阙穴治疗腹泻型肠易激综合征的疗效观察及其对血清5-HT、IL-10的影响[J].中国中医药科技,2022,29(3):356-359.
[22] 仝建松.基于Janus激酶2/信号转导和转录激活因子3信号通路探讨参苓白术散对溃疡性结肠炎模型大鼠炎症抑制作用研究[J].陕西中医,2021,42(8):1010-1015.
[23] 左云领,周西华,袁东辉,等.参倍固肠胶囊联合奥替溴铵治疗腹泻型肠易激综合征的临床研究[J].现代药物与临床,2021,36(6):1165-1170.

相似文献/References:

[1]江 晟,陆 敏 .肠康方治疗腹泻型肠易激综合征临床研究*[J].陕西中医,2019,(3):331.
　JIANG Sheng,LU Min..Clinical observation of Changkang prescription in treating predominant irritable bowel syndrome[J].,2019,(10):331.
[2]梁启放,杨 广,甘礼明.甘礼明教授论治肠易激综合征经验撷菁[J].陕西中医,2019,(12):1768.
[3]邹 维,毛靓瑶△,刘 敏,等.温针灸治疗脾胃虚弱证腹泻型肠易激综合征临床研究[J].陕西中医,2019,(12):1786.

备注/Memo

备注/Memo:
基金项目:国家自然科学基金资助项目(81873233); 陕西省中医药管理局中医药科研项目(15-JC004)
更新日期/Last Update: 2023-10-09